DUBLIN--(BUSINESS WIRE)--The "Plasmid DNA Manufacturing Market by Grade, Development Phase, Application, Disease, and by Region - Global Forecast to 2022-2033" report has been added to ResearchAndMarkets.com's offering.
The plasmid DNA manufacturing market size is estimated to be USD 525.12 million in 2022 and is expected to witness a CAGR of 13.87% during the forecast period 2023-2033. Rising demand for plasmid (pDNA) DNA, growing public understanding of cell & gene therapy, surging number of patients choose gene therapy as their treatment of choice are factors contributing to the market growth.
Additionally, higher government spending in the healthcare industry and a rise in the number of elderly people is expected to propel the market growth. Furthermore, increasing number of partnerships or collaborations between the many entities participating in this sector emphasises the growing interest in the manufacturing of plasmid DNA. However, high price of gene treatments and potential insertional mutagenesis is expected to hinder the growth.
Increasing number of partnerships or collaborations between the many entities participating in this sector emphasises the growing interest in the manufacturing of plasmid DNA. For instance, Biotage introduced Biotage PhyPrep, a revolutionary automated plasmid DNA purification solution, in June 2021. Lab personnel can save time by doing repetitive, manual work due to a major novel automated method for plasmid DNA purification. In order to create supercoiled, endotoxin-free, transfection-grade pDNA, it also makes full use of the dual flow chromatography technology of the PhyTip columns.
Surging number of patients choosing gene therapy as their treatment is predicted to fuel the market growth. Gene therapy is a cutting-edge area of medicine that offers potential new treatments for individuals with a range of ailments. For instance, intra-retinal injection of Adeno-associated AAV2 vectors expressing the therapeutic gene (RPE65) improves vision in people with Leber's Congenital Amaurosis.
Segmentation
Segmentation: Plasmid DNA Manufacturing Market Report 2022 - 2033
Grade (Revenue, USD Million), 2022 - 2033
- GMP Grade
- R&D Grade
Development Phase (Revenue, USD Million), 2022 - 2033
- Clinical Therapeutics
- Preclinical Therapeutics
- Marketed Therapeutics
Application (Revenue, USD Million), 2022 - 2033
- Cell & Gene Therapy
- Immunotherapy
- DNA Vaccines
- Others
Disease (Revenue, USD Million), 2022 - 2033
- Genetic Disorder
- Infectious Disease
- Cancer
By Region (Revenue, USD Million), 2022 - 2033
North America
- U.S
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Key Topics Covered:
1. Research Methodology
2. Introduction: Plasmid DNA Manufacturing
3. Executive Summary
4. Market Dynamics
5. Market Environment Analysis
6. COVID-19 Impact Analysis: Plasmid DNA Manufacturing Market
7. Market Analysis by Grade
8. Market Analysis by Development Phase
9. Market Analysis by Application
10. Market Analysis by Disease
11. Regional Market Analysis
12. North America Plasmid DNA Manufacturing Market
13. Europe Plasmid DNA Manufacturing Market
14. Asia PacificPlasmid DNA Manufacturing Market
15. Latin America Plasmid DNA Manufacturing Market
16. MEA Plasmid DNA Manufacturing Market
17. Competitor Analysis
18. Company Profiles
19. Conclusion & Recommendations
Companies Mentioned
- Aldevron
- Luminous BioSciences LLC
- VGXI
- Kaneka Corp.
- Cell and Gene Therapy Catapult
- Charles River Laboratories
- Nature Technology
- Eurofins Genomics
- Lonza Inc.
- Akron Biotech.
For more information about this report visit https://www.researchandmarkets.com/r/tvyt5a
